Omkar Pharmachem Ltd. Announces Special Window for Share Dematerialization

Omkar Pharmachem Ltd. has opened a special period for its shareholders to convert physical share certificates into electronic demat form. This window is active from March 25, 2026, until April 30, 2026.

The company's initiative is in response to a directive from the Securities and Exchange Board of India (SEBI). A SEBI circular issued on January 30, 2026, established a broader one-year window, from February 5, 2026, to February 4, 2027, for the transfer and dematerialization of physical securities purchased before April 1, 2019. This larger SEBI program aims to resolve long-standing investor grievances concerning physical shares, particularly for those who faced delays or documentation challenges in previous conversion attempts.

Omkar Pharmachem's specific offering allows its shareholders a defined period within the SEBI framework to complete this crucial conversion. Advertisements have been published in newspapers to ensure shareholders are aware of this opportunity.

Importance for Shareholders

This special window provides a timely and direct opportunity for shareholders holding Omkar Pharmachem's physical shares to bring their holdings up to date. Dematerializing shares is essential for compliance with modern stock market practices and ensures that shares are held securely in an electronic format, ready for future transactions.

Shareholders who do not use this period to dematerialize their physical shares may face difficulties. Unconverted physical holdings could limit future trading options or lead to additional regulatory complications.

Background on SEBI's Initiative

The SEBI circular is part of a larger effort to clean up legacy physical securities and address persistent investor issues. By providing a structured conversion pathway, SEBI seeks to enhance market transparency and operational efficiency.

Action for Shareholders

Shareholders possessing physical share certificates from Omkar Pharmachem Ltd. should now submit them for dematerialization. The company has set April 30, 2026, as the deadline for utilizing this particular conversion facility. To initiate the process, shareholders are advised to contact the company's designated channels or its registrar and follow the specified procedure.

Potential Risks

The most significant risk for shareholders is missing the April 30, 2026 deadline. After this date, converting physical shares through this streamlined process may no longer be possible, potentially leading to more complex procedures. Shareholders must also ensure all necessary documentation is accurate and submitted correctly to prevent rejection of their dematerialization requests.

Historically, Omkar Pharmachem has encountered regulatory compliance issues. The company was fined by SEBI in 2018 for delayed disclosures, highlighting the importance for shareholders to adhere strictly to the timelines and procedures associated with this dematerialization drive.

Industry Context

Omkar Pharmachem operates within the pharmaceutical and chemical sector. While this dematerialization process is administrative, it aligns with sector-wide regulatory efforts by SEBI to modernize securities management. Peers in the industry, such as Vinati Organics, Aarti Industries, and Divi's Laboratories, are also subject to these broader SEBI regulations concerning share dematerialization.

Key Dates

• Company's Special Window: March 25, 2026 – April 30, 2026
• SEBI's Broader Window: February 5, 2026 – February 4, 2027

Next Steps

Investors should complete their dematerialization process well before the April 30, 2026, company deadline. Monitoring shareholder engagement and the success rate of these conversions will be important. Any future regulatory updates from SEBI regarding physical securities should also be noted.